SCHEMBL2095089

SCHEMBL2095089

[CH2]OC(=O)Nc1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
TGM2 P21980 1/20 0.55
GAA P10253 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
MAPT P10636 2/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
TAAR1 Q96RJ0 1/20 0.48
PTPN1 P18031 1/20 0.48
FAAH O00519 1/20 0.47
ATM Q13315 1/20 0.47
MITF O75030 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2095091 0.81 SMN1; SMN2 (0.67) ALDH1A1TGM2KDM4EMEN1KMT2A
SCHEMBL9089988 0.81 MAPT (0.54) ALDH1A1GAAKDM4EMEN1KMT2A
SCHEMBL514570 0.79 TDP1 (0.57) ALDH1A1TGM2KDM4ENPC1RAB9A
SCHEMBL2096325 0.79 EGFR (0.41) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL2094114 0.79 NPC1 (0.55) ALDH1A1GAAMEN1KMT2ANPC1
SCHEMBL514280 0.79 CA12 (0.45)
SCHEMBL2291115 0.79 ALDH1A1 (0.61) ALDH1A1TGM2GAAKDM4EMEN1
SCHEMBL515017 0.79 MAPT (0.59) TGM2GAAKDM4EMEN1KMT2A
SCHEMBL6002667 0.79 MEN1 (0.54) ALDH1A1TGM2GAAKDM4EMEN1
SCHEMBL2091165 0.79 EPHX2 (0.63) ALDH1A1TGM2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed
US-4298731-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1981-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885TGM2 2418/4885GAA 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.